Diffuse midline glioma: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
{{Short description|Overview of Diffuse Midline Glioma}} | |||
==Diffuse Midline Glioma== | ==Diffuse Midline Glioma== | ||
[[File:Palliative_Care_Options_for_a_Young_Adult_Patient_with_a_Diffuse_Intrinsic_Pontine_Glioma_-_Fig._1_(cropped).png|thumb|right|MRI scan showing a diffuse midline glioma in the brainstem.]] | |||
'''Diffuse midline glioma''' (DMG) is a type of [[brain tumor]] that occurs in the midline structures of the [[central nervous system]], such as the [[thalamus]], [[brainstem]], and [[spinal cord]]. These tumors are characterized by their infiltrative nature, making them difficult to surgically remove. They are most commonly diagnosed in children and are associated with a poor prognosis. | |||
==Classification== | |||
Diffuse midline gliomas are classified as [[high-grade gliomas]], specifically as [[World Health Organization]] (WHO) grade IV tumors. They are often associated with a specific genetic mutation in the [[H3 K27M]] gene, which is a hallmark of this tumor type. This mutation leads to changes in the [[epigenetic]] regulation of gene expression, contributing to the aggressive nature of the tumor. | |||
==Pathophysiology== | ==Pathophysiology== | ||
[[File:Mutations_in_diffuse_intrinsic_pontine_glioma_samples_from_several_anatomical_locations_-_Ncomms11185-f1.jpg|thumb|left|Genetic mutations associated with diffuse intrinsic pontine glioma.]] | |||
The pathophysiology of diffuse midline glioma involves the infiltration of tumor cells into the surrounding brain tissue. The H3 K27M mutation results in a global reduction of [[histone]] H3 lysine 27 trimethylation, which affects the expression of numerous genes involved in cell growth and differentiation. This mutation is thought to drive the oncogenic process in these tumors. | |||
[[File:Mutations_in_diffuse_intrinsic_pontine_glioma_samples_from_several_anatomical_locations_-_Ncomms11185-f1.jpg|thumb|left| | |||
==Clinical Presentation== | ==Clinical Presentation== | ||
Patients with diffuse midline glioma typically present with symptoms related to the location of the tumor. For example, tumors in the [[brainstem]] may cause [[cranial nerve]] deficits, [[ataxia]], and [[dysphagia]]. Tumors in the thalamus can lead to [[hemiparesis]], [[sensory deficits]], and [[altered mental status]]. | |||
Patients with diffuse midline glioma typically present with symptoms related to the location of the tumor. For example, tumors in the brainstem may cause cranial nerve deficits, | |||
==Diagnosis== | ==Diagnosis== | ||
[[File:Integrated_Molecular_Meta-Analysis_of_1,000_Pediatric_High-Grade_and_Diffuse_Intrinsic_Pontine_Glioma_-_graphical_abstract.jpg|thumb|right|Molecular analysis of pediatric high-grade gliomas.]] | |||
Diagnosis of diffuse midline glioma is | Diagnosis of diffuse midline glioma is typically made using [[magnetic resonance imaging]] (MRI), which reveals a diffusely infiltrative lesion in the midline structures. [[Biopsy]] may be performed to confirm the diagnosis and identify the presence of the H3 K27M mutation. | ||
==Treatment== | ==Treatment== | ||
The treatment of diffuse midline glioma is challenging due to the tumor's location and infiltrative nature. [[Radiation therapy]] is the mainstay of treatment and can provide temporary relief of symptoms. However, the tumor often recurs, and the overall prognosis remains poor. [[Chemotherapy]] has limited effectiveness, and research is ongoing to find more effective treatments. | |||
==Prognosis== | ==Prognosis== | ||
The prognosis for patients with diffuse midline glioma is generally poor, with a median survival of less than one year from diagnosis. The presence of the H3 K27M mutation is associated with a particularly aggressive clinical course. | |||
The prognosis for patients with diffuse midline glioma is poor, with a median survival of less than one year. The | |||
==Research Directions== | ==Research Directions== | ||
[[File:Palliative_Care_Options_for_a_Young_Adult_Patient_with_a_Diffuse_Intrinsic_Pontine_Glioma_-_Fig._2_(cropped).png|thumb|left|Research into palliative care options for patients with diffuse intrinsic pontine glioma.]] | |||
Research into diffuse midline glioma is focused on understanding the molecular mechanisms driving tumor growth and identifying potential therapeutic targets. Novel treatment approaches, including targeted therapies and [[immunotherapy]], are being investigated in clinical trials. | |||
[[ | |||
==Related Pages== | ==Related Pages== | ||
* [[ | * [[Glioma]] | ||
* [[Pediatric | * [[Brain tumor]] | ||
* [[Pediatric oncology]] | |||
* [[Radiation therapy]] | * [[Radiation therapy]] | ||
[[Category:Brain tumors]] | [[Category:Brain tumors]] | ||
[[Category:Pediatric cancers]] | [[Category:Pediatric cancers]] | ||
[[Category:Neurology]] | |||
Revision as of 04:53, 6 March 2025
Overview of Diffuse Midline Glioma
Diffuse Midline Glioma
Diffuse midline glioma (DMG) is a type of brain tumor that occurs in the midline structures of the central nervous system, such as the thalamus, brainstem, and spinal cord. These tumors are characterized by their infiltrative nature, making them difficult to surgically remove. They are most commonly diagnosed in children and are associated with a poor prognosis.
Classification
Diffuse midline gliomas are classified as high-grade gliomas, specifically as World Health Organization (WHO) grade IV tumors. They are often associated with a specific genetic mutation in the H3 K27M gene, which is a hallmark of this tumor type. This mutation leads to changes in the epigenetic regulation of gene expression, contributing to the aggressive nature of the tumor.
Pathophysiology
The pathophysiology of diffuse midline glioma involves the infiltration of tumor cells into the surrounding brain tissue. The H3 K27M mutation results in a global reduction of histone H3 lysine 27 trimethylation, which affects the expression of numerous genes involved in cell growth and differentiation. This mutation is thought to drive the oncogenic process in these tumors.
Clinical Presentation
Patients with diffuse midline glioma typically present with symptoms related to the location of the tumor. For example, tumors in the brainstem may cause cranial nerve deficits, ataxia, and dysphagia. Tumors in the thalamus can lead to hemiparesis, sensory deficits, and altered mental status.
Diagnosis
Diagnosis of diffuse midline glioma is typically made using magnetic resonance imaging (MRI), which reveals a diffusely infiltrative lesion in the midline structures. Biopsy may be performed to confirm the diagnosis and identify the presence of the H3 K27M mutation.
Treatment
The treatment of diffuse midline glioma is challenging due to the tumor's location and infiltrative nature. Radiation therapy is the mainstay of treatment and can provide temporary relief of symptoms. However, the tumor often recurs, and the overall prognosis remains poor. Chemotherapy has limited effectiveness, and research is ongoing to find more effective treatments.
Prognosis
The prognosis for patients with diffuse midline glioma is generally poor, with a median survival of less than one year from diagnosis. The presence of the H3 K27M mutation is associated with a particularly aggressive clinical course.
Research Directions
Research into diffuse midline glioma is focused on understanding the molecular mechanisms driving tumor growth and identifying potential therapeutic targets. Novel treatment approaches, including targeted therapies and immunotherapy, are being investigated in clinical trials.
.png){kind=link}
.png){kind=link}